Cat. No. |
Product Name |
Information |
PC-42052 |
SNS-032
CDK2/7/9 inhibitor
|
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK 2/7/9 with IC50 of 48 nM/62 nM/4 nM, respectively. |
PC-42616 |
Dinaciclib
CDK inhibitor
|
Dinaciclib (SCH 727965) is a potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively. |
PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
PC-22396 |
CDKL2 inhibitor 9
CDKL2 inhibitor
|
CDKL2 inhibitor 9 is a selective cyclin-dependent kinase-like 2 (CDKL2, KKIAMRE, P56) chemical probe inhibitor with enzyme IC50 of 230 nM in radiometric enzymatic assays. |
PC-22118 |
AZD8421
CDK2 inhibitor
|
AZD8421 (AZD-8421) is a potent, highly selective CDK2 inhibitor with IC50 of 9 nM, >300-fold selectivity over CDK9. |
PC-22032 |
KY-273
CDK8/19 inhibitor
|
KY-273 (KY273) is a potent, specific CDK8/19 inhibitor with IC50 of 29.1 and 44.7 nM respectively, promotes osteoblast differentiation and has cortical-bone-selective osteogenic effects. |
PC-21964 |
dCeMM4
Cyclin K degrader
|
dCeMM4 is a small glue degrader, induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. |
PC-21963 |
dCeMM3
Cyclin K degrader
|
dCeMM3 is a small glue degrader, induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. |
PC-21962 |
dCeMM2
Cyclin K degrader
|
dCeMM2 is a small glue degrader, induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex. |